Mechanism of Action
We are developing transformative personalized targeted T cell therapies for cancers to unleash the patient’s immune response effectively against cancer. Geneius’s Targeted DiversiTy™ platform is designed to re-educate the patient’s natural T cells to become more responsive to multiple tumor specific antigens that were previously overlooked by their immune system. This process delivers a specific and durable immune response that we believe is less susceptible to tumor immune evasion. This re-education of the patient’s T cells without genetic engineering is more effectively done outside of the patient’s body in a lab process designed by Geneius.
Geneius produces T cells that are reactive with previously overlooked antigens and that we believe will result in superior killing, homing and duration of response. The company has created a good manufacturing process (GMP) to produce of T cells from peripheral blood for infusion into the patient as we are developing transformative personalized targeted T cell therapies for cancers to unleash the patient’s immune response effectively against cancer. We believe that our products will create a new and effective immune response that will seek and destroy cancer all over the body and lead to a durable anti-cancer response. We have the pre-clinical data on our lead product candidate for EBV+, NHL, gastric and solid cancers that will enable us to treat the first patient shortly.
Geneius Biotechnology developed a GMP for manufacturing T cells when developing transformative personalized targeted T cell therapies for cancers. Geneius named this good manufacturing process T Direct. T Direct is a process for producing T cells to previously overlooked antigens. From 100 ml of blood of a patient, we:
collect peripheral blood mononuclear cells (PBMCs); and
pulse these PBMCs with antigenic peptides to get 4 billion cells.
The T cells are then grown in a culture including a proprietary cytokine cocktail. In 4 weeks, enough T cells have been generated with the appropriate antigen specificity and phenotypes (killing, homing and duration of response) to be infused into the patient.